Drugs for disruptive features in dementia

Drug and Therapeutics Bulletin

Volumn 41, Issue 1, 2003, Pages 1-4

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AGGRESSION; AGITATION; AKATHISIA; APATHY; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; HYPOTENSION; HYPOTHERMIA; INFORMED CONSENT; MENTAL DISEASE; META ANALYSIS; PERIPHERAL EDEMA; PREVALENCE; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR DISORDER; PSYCHOSIS; PSYCHOTHERAPY; SOMNOLENCE; TARDIVE DYSKINESIA; UNITED KINGDOM; VISUAL IMPAIRMENT;

EID: 0037269698     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2003.4111     Document Type: Article

References (39)

1. Devanald DP et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997; 54: 257-63.
2. Lykestsos CG et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157: 708-14.
3. Macdonald AJ et al. Dementia and use of psychotropic medication in non-'Elderly Mentally Infirm' nursing homes in South East England. Age Ageing 2002; 31: 58-64.
4. Lawlor B, Bhriain SN, Psychosis and behavioural symptoms of dementia: defining the role of neuroleptic interventions. Int J Geriatr Psychiatry 2001; 16: S2-6.
5. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry 2002; 180: 144-7.
6. Scottish Intercollegiate Guidelines Network. Interventions in the management of behavioural and psychological aspects of dementia. Pilot edition, February 1998 [online]. Available at http://www.sign.ac.uk/guidelines/index.html. (Accessed 9 December 2002).
7. Ballard C et al. A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia. Int Psychogeriatr 1997; 9: 57-64.
8. Hope T et al. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br J Psychiatry 1999; 174: 39-44.
9. Alessi CA et al. A randomized trial of a combined physical activity and environmental intervention in nursing home residents: do sleep and agitation improve? J Am Geriatr Soc 1999; 47: 784-91.
10. Ballard CG et al. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2002; 63: 553-8.
11. Hopman-Rock M et al. The effects of a psychomotor activation programme for use in groups of cognitively impaired people in homes for the elderly. Int J Geriartr Psychiatry 1999; 14: 633-42.
12. Lyketsos CG et al. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Int J Geriatr Psychiatry 1999; 14: 520-5.
13. Opie J et al. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust New Zealand J Psychiatry 1999; 33: 789-99.
14. Teri L et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1271-8.
15. Department of Health, November 2001. Seeking consent: working with older people [online]. Available at http://www.doh.gov.uk/consent/ olderpeople.pdf. (Accessed 16 December 2002).
16. Department of Health, March 2001. Reference guide to consent for examination or treatment [online]. Available http://www.doh.gov.uk/ consent/refguide.htm. (Accessed 16 December 2002).
17. Schneider LS et al. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriartr Soc 1990; 38: 353-63.
18. Lanctot KL et al. Efficacy and safety of neuroleptics in behavioural disorders associated with dementia. J Clin Psychiatry 1998; 59: 550-61.
19. Lonergan E et al. Haloperidol for agitation in dementia (Cochrane Review). In The Cochrane Library, Issue 4, 2002. Oxford: Update Software. (Last substantive update 27 February 2002).
20. Woerner MG et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155: 1521-8.
21. McShane R et al. Do neuroleptics hasten cognitive decline in dementia? Prospective study with necroscopy follow up. BMJ 1997; 314: 266-70.
22. Katz IR et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-15.
23. De Deyn PP et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55.
24. Street JS et al. Olanzapine-treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57:968-76.
25. Porsteinsson AP et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 58-66.
26. Tariot PN et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61.
27. Katona CL et al. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriat Psychiatry 1998; 13: 100-8.
28. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Br J Psychiatry 1990; 157: 894-901.
29. Petraca G et al. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 270-5.
30. Roth M et al. Moclobemide in elderly patients with cognitive decline and depression. Br J Psychiatry 1996; 168:149-57.
31. Joint Formulary Committee. British National Formulary. Edition 44. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, September 2002.
32. Birks J et al. Donepezil for mild and moderate Alzheimer's disease (Cochrane Riview). In The Cochrane Library, Issue 4, 2002. Oxford: Update Software. (Last substantive update 30 August 2000).
33. Olin J, Schneider L. Galantamine fo Alzheimer's disease (Cochrane Review). In The Cochrane Library, Issue 4, 2002. Oxford: Update Software. (Last substantive update 7 May 2002).
34. Birks J et al. Rivastigmine for Alzheimer's disease (Cochrane Riview). In The Cochrane Library, Issue 4, 2002. Oxford: Update Software. (Last substantive update 30 August 2000).
35. Tariot PN et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9.
36. Feldman H et al. A 24-week, randomised, double-blind study of donezepil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
37. McKeith I et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
38. McGrath AM, Jackson GA. Survey of neuroleptic prescribing in resident of nursing homes in Glasgow. BMJ 1996; 312: 611-2.
39. Semla TP et al. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42: 648-52.